



Regional Chapter Annual Report - 2015

**Chapter
Region**

Russia St. Petersburg
Europe

President

Alexey Kolbin, MD, PhD, Doctor of Science Head of the department of clinical pharmacology and evidence-based medicine First Pavlov State Medical University of St. Petersburg; Professor of Department of Pharmacology, Faculty of Medicine St. Petersburg State University; alex.kolbin@mail.ru

**President-Elect
Past President**

Edwin Zvartau, MD, PhD, Doctor of Science, Professor, Head of the Department of Pharmacology; zvartau@spb-gmu.ru

**Secretary
Members**

Alexey Kurilev, MD, Department of clinical pharmacology and evidence-based medicine First Pavlov State Medical University of St. Petersburg; alexey-kurilev@yandex.ru
15

I. The following articles have been published in Russian and International journals about pharmacoeconomical and health technology assessment researches:

1. Pharmacoeconomic analysis of using everolimus in comparison with aksitinib in second-line therapy of metastatic renal cancer. *Clinical Pharmacology and Therapy*, 2015. - 24 (1). - P.92-96. Kolbin A.S., Frolov M.Y., Kurilev A.A., Proskurin M.A., Balikina Y.E.
2. About evaluation of the amount of drugs. *Inter-medical*. 2015. - № 1(7). - P.91-97. Popov D.A., Prasolov A.V., Kolbin A.S.
3. Clinical and Pharmacoeconomic Reasonability of Using Probiotic Enterococcus Strain for the Complex Developmental Care Program for Premature Infants. *Pediatric Pharmacology* - 2015. - V.12. - № 1. - P.22-30. Gonchar N.V., Lo Skiavo L.A., Suvorov A.N., Shabalov N.P., Kolbin A.S., Kasimova A.R.
4. Pharma 2020. New experience of FSPbSMU named after Academician Pavlov study programs. *Science Almanac of First Saint-Petersburg State Medical University named after Academician I.P. Pavlov* - 2015. - Issue №6. - P.3-4. Kolbin A.S., Khrustalev M.B.
5. Safety of biologic drugs - new realities. *Medical Academic Journal*, 2015. - V.-15.- № 1. - P.22-33. Kolbin A.S., Toporov A.A.
6. Pharmacoeconomic analysis of denosumab use in breast cancer patients with bone metastasis. *Qualitative Clinical Practice*. - 2015. - No1.- P.10-16. Kolbin A.S., Kurilev A.A., Proskurin M.A., Balikina Y.E.
7. Comparative clinical and economic assessment of cabazitaxel and abirateron in prostate cancer based on clinical researches and real-life clinical practice data. *Qualitative Clinical Practice*. - 2015. - No1.- P.18-31. Kolbin A.S., Kurilev A.A., Pavlysh A.V.
8. Pharmacoeconomic analysis of using ibrutinib as first-line therapy of chronic lympholeukosis in patients with 17p-deletion. *Qualitative Clinical Practice*. - 2015. - No1.- P.32-43. Kolbin A.S., Vilum I.A., Proskurin M.A., Balikina Y.E.
9. Adverse effects of systemic interferons. *Safety*

Describe your Chapter's accomplishments for 2015 with regard to Scientific and Educational activities.



Regional Chapter Annual Report - 2015

and Risk of Pharmacotherapy. - 2015. - №2(7). - P.7-14. Toporov A.A., Kolbin A.S. 10. Translational research. Prospects in Russia. Scientific Centre for Expert Evaluation of Medical Products Bulletin. - 2015. - №1. - P.40-45. Kolbin A.S., Gapeshin R.A., Malyshev S.M. 11. What should be considered if you decide to build your mathematical model for predicting the development of bacterial resistance? Recommendations based on a systematic review of the literature. *Frontiers in Microbiology*. 2015; 6:352. Arepeva M., Kolbin A., Balykina Y., Kurilev A., Sidorenko S. 12. Modeling of drugs inclusion in restrictive list (example - VED). Data analysis of 2014. *Remedium*. - 2015. - P.58-63. Prasolov A.V., Kolbin A.S., Maximkina E.A., Golant Z.M., Polyshin Y.S., Kurilev A.A., Vilum I.A., Balikina Y.E. 13. Pharmaceutical market assessment at optimal patient's strategy choice. Materials of VII International scientific professional conference. Saint-Petersburg. 2015. - Vol.1.- P.131-138. Popov D.A., Prasolov A.V., Kolbin A.S. 14. A study of expectations of market participants to the competences of clinical project manager in clinical trials of pharmaceutical products. *Remedium*. 2015. - may - P.40-44. Malikov A.Y., Verbitskaya E.V., Dodonova I.V., Kochorova L.V., Semenov Tyan-Shanskiy V.L., Tolmachev A.N., Kolbin A.S., Vishnyakov N.I., Khrustalev M.B. 15. Pharmacoeconomic analysis of the use of Ribomustin® in therapy of the first line of a multiple myeloma for patients more senior 65 years old. *Pharmacoeconomics. Modern pharmacoeconomics and pharmacoepidemiology*. 2015. - Vol. 8. - № 1. - P.39-46. Kolbin A.S., Vilum I.A., Proskurin M.A., Balikina Y.E. 16. Chapter 14. Pharmacotherapy during pregnancy. P.204-227. *Perinatology Guideline/ red. Ivanov D.O. - SPb.: Inform-Navigator, 2015. - 1216 p.* Ivanova A.A., Zagorodnikova K.A., Kolbin A.S. 17. Chapter 15. Pharmacotherapy during lactation. P.227-234. *Perinatology Guideline/ red. Ivanov D.O. - SPb.: Inform-Navigator, 2015. - 1216 p.* Ivanova A.A., Zagorodnikova K.A., Kolbin A.S. 18. Budget impact analysis of chronic myeloleukosis therapy with tyrosine-kinase inhibitor nilotinib as first- and second-line treatment. *Clinical Pharmacology and Pharmacotherapy*. - 2015. - Vol. 24.- №2. - P.91-96. Kolbin A.S., Frolov M.Y., Kurilev A.A., Vilum I.A., Proskurin M.A., Balikina Y.E. 19. A review of global requirements to the competencies of clinical project managers and potential adaptation to Russian reality. *Remedium*. - 2015. - June. - P.55-59. Verbitskaya E.V., Dodonova I.V., Kochorova L.V., Semenov Tyan-Shanskiy V.L., Tolmachev A.N., Malikov A.Y., Kolbin A.S., Vishnyakov N.I., Khrustalev M.B. 20. Reasons for difficulty of the pharmacoeconomic analysis for orphan drugs. Ways for solutions. *Pharmacoeconomics. Modern pharmacoeconomics and pharmacoepidemiology*. 2015. - Vol. 8.- №2. - P.3-10. Pavlysh A.V., Kolbin A.S., Gapeshin R.A., Malyshev S.M. 21. Pharmacoeconomic analysis of using botulinic toxin drugs in complex therapy



Regional Chapter Annual Report - 2015

of post-stroke spasticity. Qualitative Clinical Practice. - 2015. - №3. - P.19-30. Kolbin A.S., Vilum I.A., Proskurin M.A., Balikina Y.E. 22. Pharmacoeconomic analysis of using tiotropium bromide (spiriva® respimat®) as add-on therapy in patients with bronchial asthma in Russian Federation. Russian Allergology Journal. No 5-2015. - P.54-63. Kolbin A.S., Galankin T.L., Proskurin M.A., Balikina Y.E. 23. BUDGET IMPACT ANALYSIS OF THE TREATMENT OF CHRONIC MYELOID LEUKEMIA WITH TYROSINE KINASE INHIBITORS - NILOTINIB IN THE FIRST AND SECOND LINES OF THERAPY ISPOR. 18TH ANNUAL EUROPEAN CONGRESS RESEARCH ABSTRACTS. Value in health. 2015:18(7); A442 Kolbin A, Frolov M, Kurylev A, Vilum I, Balykina Y, Proskurin M 24. INVESTIGATING LEVELS OF BACTERIAL RESISTANCE AND ANTIBIOTIC CONSUMPTION IN THE ST. PETERSBURG STATE MEDICAL UNIVERSITY ISPOR. 18TH ANNUAL EUROPEAN CONGRESS RESEARCH ABSTRACTS. Value in health. 2015:18(7); A515 Kolbin A, Lawson R, Kurylev A, Arepieva M3, Balykina Y, Spiridonova A, Mukhina N, Sidorenko S 25. PHARMACOECONOMIC ANALYSIS OF THE USE OF EVEROLIMUS COMPARED TO AXITINIB IN SECOND LINE THERAPY OF PATIENTS WITH METASTATIC RENAL CELL CARCINOMA ISPOR. 18TH ANNUAL EUROPEAN CONGRESS RESEARCH ABSTRACTS. Value in health. 2015:18(7); A443 Kolbin A, Frolov M, Kurylev A, Balykina Y, Proskurin M 26. Pharmacoeconomic analysis of using botulinic toxin drugs in complex therapy of post-stroke spasticity. Qualitative Clinical Practice, 2015; 3:19-29 Kolbin A.S., Vilum I.A., Proskurin M.A., Balikina Y.E. 27. Pharmacoeconomic analysis of using Vemurafenib as a treatment of non-resectable or metastatic melanoma in patients with BRAF V600 mutation. Pharmacoeconomics. Theory and Practice. - 2015. - Vol. 3(4). - P.14-19. Kolbin A.S., Kurilev A.A., Vilum I.A., Proskurin M.A., Balikina Y.E. 28. Pharmacoepidemiology. Guidance manual. Pharmacoepidemiology: guideline / Galankin T.L., Verbitskaya E.V.; under red. Kolbin A.S. - SPb. : Publishing house of SPbSMU, 2015. - 40 p. Galankin T.L., Verbitskaya E.V., Kolbin A.S. 29. The data retrieval optimization from the perspective of evidence-based medicine Proceedings of the 2015 Federated Conference on Computer Science and Information Systems, M. Ganzha, L. Maciaszek, M. Paprzycki (eds)., IEEE, 2015, Vol. 5, pages 323-328. doi V. Dobrynin, J. Balykina, M. Kamalov, A. Kolbin, E. Verbitskaya, M. Kasimova 30. Pharmacoeconomical aspects of using apixaban for prevention of cardio-vascular complications in patients with non-valvular atrial fibrillation. Rational Pharmacotherapy in Cardiology. 2015. V. 11. № 1. P. 60-62. Rudakova A.V. 31. Antiviral therapy of chronic hepatitis C (1 genotype) in Russia: costs and effectiveness. Journal of Infectology.-2015.-№1.- 91-98. Rudakova A.V., Gusev D.A., Uscov A.N., Lobzin Y.V.



Regional Chapter Annual Report - 2015

32. Therapy with gefitinib of non-resectable non-small cell lung cancer in patients with EGFR gene mutation: pharmacoeconomic aspects. *Problems in Oncology*. 2015. V. 61. № 4. P. 676-680. Procenko S.A., Rudakova A.V.
33. Budget impact analysis of thromboembolic complications prevention by using oral anticoagulants in patients with non-valvular atrial fibrillation. *Rational Pharmacotherapy in Cardiology*. 2015. V. 11. № 3. P. 267-271. Rudakova A.V.
34. Pharmacoeconomic aspects of venous thromboembolic complications prevention during endoprosthesis replacement of large joints. *Rational Pharmacotherapy in Cardiology*. 2015. V. 11. № 3. P. 287-292. Rudakova A.V.
35. Cost-effectiveness evaluation for the analysis of thrombocytic reactivity with VERIFYNOW P2Y₁₂ method in patients after acute coronary syndrome. *Rational Pharmacotherapy in Cardiology*. 2015. V. 11. № 4. P. 359-364. Rudakova A.V., Lomakin N.V.
36. New oral anticoagulants cost effectiveness in therapy and secondary prevention of venous thromboembolism. *Rational Pharmacotherapy in Cardiology*. 2015;11(5): 496-503. Rudakova A.V.
37. Efficiency Of Expenses Of Gefitinibum In Patients With Non-Small Cell Lung Cancer As A Second Line Therapy Value Health. 2015 Nov;18(7):A464-5. doi: 10.1016/j.jval.2015.09.1213. Epub 2015 Oct 20. Rudakova AV, Meshkov DO, Khabriev RU, Bezmelnitsyna LY.
38. Pharmacoeconomic aspects of glaucoma's therapy by prostaglandin analogs in patients with evidence of eye surface pathology. *Ophthalmologic News*. 2015. V. 8. № 1. P. 99-103. Rudakova A.V.
39. Cost effectiveness of aksitinib in patients with metastatic renal cell cancer after cytokinic therapy. *Medical Technologies. Assessment and Choice*. 2015. № 1 (19). P. 50-54. Rudakova A.V.
40. Clinical and pharmacoeconomic aspects of surfactant replacement therapy of respiratory distress-syndrome in premature newborns by animal-based drugs. *Neonatology: News, Opinions, Trainings*. 2015. № 2 (8). P. 51-56. Rindin A.Y., Lenushkina A.A., Antonov A.G., Rudakova A.V., Ivanov D.O.
41. Pharmacoeconomic analysis of first-line antiretroviral therapy. *HIV infection and Immunosuppressive Disorders*. - 2015.- V. 7, №1. - P. 29-39. Toropov S.E., Rudakova A.V., Zakharova N.G., Sizova N.V., Dvorak S.I., Belyakov N.A., Rassokhin V.V.
42. Results of pharmacoepidemiology research of arterial hypertension PIFAGOR IV: doctor's compliance. *Russian Journal of Cardiology* 2015, 1(117): 59-66. Leonova M.V., Steinberg L.L., Belousov Y.B., Belyavskaya D.V., Vidrina O.I., Pasternak E.Y. and group of researchers.
43. Cost-minimization analysis of using acetylsalicytic acid drugs in cardiologic patients of elderly age. *Qualitative Clinical Practice*, №1, 2015, p. 3-9. Belousov D.Y., Afanasyeva E.V.
44. Comparative clinicoeconomic analysis of lodantipirin for an emergency prevention of tick-borne encephalitis. *Qualitative Clinical Practice*, №1, 2015, p. 44-52. Ashihmin Y.I., Belousov D.Y., Afanasyeva



Regional Chapter Annual Report - 2015

- E.V. 45. Pharmacoeconomic analysis of using long-term pramipexol as monotherapy on early stages of Parkinson disease. *Qualitative Clinical Practice*, №1, 2015, p. 53-65. Belousov D.Y., Afanasyeva E.V. 46. Pharmacoeconomic analysis of using Movalis in patients with osteoarthritis and rheumatoid arthritis. *Qualitative Clinical Practice*, №1, 2015, p. 66-77. Tsvetkova E.S., Belousov D.Y., Afanasyeva E.V. 47. Pharmacoepidemiology analysis of sugar-lowering drugs use by patients with type 2 diabetes mellitus in Moscow. *Diabetes Mellitus*. 2015;(2):32-46. Kalashnikova M.F., Belousov D.Y., Suntsov Y.I., Kantemirova M.A., Dedov I.I. 48. Comparative pharmacoeconomic evaluation of modern antidepressant drugs used as monotherapy. *Qualitative Clinical Practice*, №3, 2015, p. 3-18. Cheberda A.E., Belousov D.Y., Ziryakov S.K. 49. Cost-minimization analysis of using «Antiseptic spirituous drapes «M.K.Aseptika». *Qualitative Clinical Practice*, №3, 2015, p. 72-88. Belousov D.Y., Afanasyeva E.V. 50. Comparative pharmacoeconomic analysis of using ceftarolin in treatment of complicated skin and soft tissue infections. *Qualitative Clinical Practice*, №3, 2015, p. 43-59. Ziryakov S.K., Belousov D.Y., Afanasyeva E.V. 51. Clinicoeconomic analysis of using Giotrif® (afatinib) drug in first-line treatment of regional or metastatic non-small cell lung cancer with Del19-mutation of epidermal growth factor receptor (EGFR). *Malignant tumors*, 2015;1;4:35-47. Gorbunova V.A., Orlov S.V., Ziryakov S.K., Belousov D.Y. 52. Pharmacoeconomic analysis of using etravirin in comparison with raltegravir in complex therapy of HIV-infection in adult patients, which were treated with antiretroviral drugs. *Qualitative Clinical Practice*, №3, 2015, p. 60-71. Ashihmin Y.I., Belousov D.Y. 53. Clinicoeconomic analysis of using biologic drugs in treatment of moderate and severe forms of psoriasis. *Qualitative Clinical Practice*, №3, 2015, p. 34-42. Kubanov A.A., Ziryakov S.K., Belousov D.Y. 54. Cost-effectiveness analysis of antisecretory treatment of acute gastroduodenal ulcerative bleedings. *Doctor.ru. Gastroenterology*. 2015. №12 (113). P. 65-69. Chernousova E.A., Hatkov I.E., Belousov D.Y., Chudnih S.M., Domrachev S.A. 55. Clinical and economical aspects of novel approaches to the approaches to the treatment of chronic heart failure decompensation. *Russian Cardiology Journal*. 2015. № 3 (119). P. 103-107 Zyryanov S. K. Arutyunov G. P. 56. Pharmacoeconomic analysis of Giotrif® (afatinib) as first-line treatment of metastatic non-small cell lung cancer with Del19 mutation of epidermal growth factor receptor (EGFR) gene. *Malignant Tumors*. 2015. № 4. P. 35-47 Gorbunova V. A., Zyryanov S. K., Orlov S. V., Belousov D. Yu. 57. Comparative pharmacoeconomic assessment of modern antidepressants used in monotherapy. *Good Clinical Practice*. 2015. № 3. P. 3-18 Zyryanov S. K. Cheberda A. E. Belousov D. Yu. 58. Clinical and economic analysis of use of biologic drugs



Regional Chapter Annual Report - 2015

for treatment of moderate and severe forms of psoriasis Good Clinical Practice. 2015. № 3. P. 34-42 Kubanov A. A. Zyryanov S. K. Belousov D. Yu. 59. Comparative pharmacoeconomic analysis of ceftaroline in treatment of complicated skin and soft tissue infections Good Clinical Practice. 2015. № 3. P. 43-59 Zyryanov S. K. Belousov D. Yu. Afanasieva Ye. V. II. Oral Presentations at the Russian Meeting on health economics and health technology assessment researches: 1. As a section of Russian Pediatrics Congress "The Present and the Past of Target Approach in Asthma Treatment: Advances and Perspectives of Anti-IgE Therapy" Russian Academy of Medical Science, The Union of Pediatricians of Russia Pharmacoeconomic aspects of Anti-IgE Therapy 14/1/2015 Moscow 2. Expert Council on Chronic Obstructive Pulmonary Disease Treatment Russian Academy of Medical Science Economic Aspects of COPD 18/1/2015 Moscow 3. Interregional Scientific and Practice Conference "Protocols of Antibacterial Therapy of Sepsis in the North-Western Federal District" Health Committee, Territorial Mandatory Medical Insurance Fund The Use of Antibacterial Drugs in Hospitals of St Peterburg: Results of Pharmacoepidemiologic Analysis 9/4/2015 St Petersburg 4. Educational Seminar "Pharmacotherapy of Nosocomial Fungal Infections: Current Recommendations and Clinical Practice" North Western State Medical University named after I. I. Mechnikov Results of Pharmacoeconomic Research - A Criterion for Drug Choice 17/4/2015 St Petersburg 5. All-Russian Meeting "Current Issues in Clinical Pharmacology and Drug Provision" Ministry of Healthcare Modeling the Inclusion of Drugs into the Russian Government's Reimbursement Lists. (Vital and Most Important Drugs as an Example). An analysis of the 2014 data. 14/5/2015 Samara 6. XVII International Congress on Antimicrobial Therapy The Interregional Association for Clinical Microbiology and Antimicrobial Chemotherapy (IACMAC), European Society for Clinical Microbiology and Infectious Diseases (ESCMID), Alliance for the Prudent Use of Antibiotics (APUA), International Society of Chemotherapy (ISC), The Use of Antibacterial Drugs in Hospitals of St Peterburg: Results of Pharmacoepidemiologic Analysis 22/5/2015 Moscow 7. Scientific and Practice Conference "Molecular Biology in Oncology: From Fundamental Science to Practice" Ministry of Healthcare of Khabarovsk Krai, Far Eastern State Medical University Tyrosine Kinase Inhibitors - Novel Opportunities for Treatment of Non-Small Cell Lung Cancer. Gilotrif (afatinib) - Pharmacoeconomic Expediency of the Use 23/5/2015 Khabarovsk 8. Russian-Chinese Scientific and Practical Conference on Medical Microbiology and Clinical Mycology (XVIII Kashkin Readings) Ministry of Healthcare of the Russian Federation, North Western State Medical University named after I. I. Mechnikov, Harbin Medical University Pharmacoepidemiology of Antibacterial Drugs in St



Regional Chapter Annual Report - 2015

Petersburg 10/6/2015 St Petersburg 9. Scientific Conference "Rational Pharmacotherapy in Contemporary Endocrinology" Health Committee of St Petersburg, Professional Association of Clinical Pharmacologists of St Petersburg Adaptation of PE model for Russia by the example of Insulin Degludec 25/6/2015 St Petersburg 10. International Innovation Forum St Petersburg City Government Health Technology Assessment (HTA): history, terminology, reasons for emergence, and basic principles. 7/10/2015 St Petersburg 11. Anniversary X Scientific and Practice Conference with International Participation "Rational Pharmacotherapy 2015" Health Committee of St Petersburg, Professional Association of Clinical Pharmacologists of St Petersburg Pharmacoeconomics of Innovative Decisions in Treatment of Inoperable or Metastatic Skin Melanoma 9 /10/2015 St Petersburg 12. X National Congress of Physicians Dedicated to 140th Anniversary of M. P. Konchalovsky Ministry of Healthcare of the Russian Federation, Russian Scientific Medical Society of Physicians Selection of generic drugs based on health technology assessment 16/10/2015 Moscow 13. Рациональная фармакотерапия в педиатрии. Health Committee, РФ Pharmacoeconomics of antibiotics in St Petersburg 28/10/2015 St Petersburg 14. II International Scientific and Practice Conference "Health Technology Assessment: Ways of Development in Russia" Ministry of Healthcare Decree of the Government No 871. Development of Requirements 2/11/2015 Moscow 15. Evidence-Based Medicine: Advances and Barriers Ministry of Healthcare of Tatarstan, Cochrane Working Group, International Association of Clinical Pharmacologists and Pharmacists Comparative Effectiveness - a Contemporary Demand in Evidence-Based Decision-Making 7-8/11/2015 Kazan 16. Scientific and Practical Conference "Current Issues in Pulmonology: Advances and Perspectives", Vladimir Healthcare Department of Vladimir Oblast Clinical and economic benefits of free formoterol/budesonide combinations in treatment of asthma 04/4/2015 Vladimir 17. All-Russian Scientific and Practical Conference "Current Issues in Clinical Pharmacology and Drug Provision" dedicated to 85th Anniversary of Clinics of the Samara State Medical University Ministry of Healthcare of the Russian Federation Clinical and Economic Aspects of New Technologies in Treatment of Decompensated Heart Failure 15/5/2015 Samara 18. XI Transregional Conference "Current Issues in Providing Quality Drug and Medical Care" Ministry of Healthcare of the Russian Federation Pharmacoeconomic Basis for Optimization of Drug Therapy of Astma in the Russian Federation 28/6/2015 Sochi 19. 1st Annual Conference "Pharmacoeconomics and Health Technology Assessment in the Moscow Region" Healthcare Department of the City of Moscow Lung Cancer Pharmacotherapy - To What Extent Are Costs Effective?



Regional Chapter Annual Report - 2015

18/9/2015 Moscow 20. V Social Forum of Russia Ministry of Healthcare of the Russian Federation, The State Duma of the Russian Federation Providing the Availability of Drugs in Current Socioeconomic Situation
16/11/2015 Moscow 21. 3rd Transregional Scientific and Practical Symposium "HIV Medicine and Pharmacoeconomics" Russian Academy of Science (RAS), Health Committee (HC), Pavlov First Saint Petersburg State Medical University, Institute of Experimental Medicine of North-Western Section of RAS, St Petersburg Centre for Prevention and Control of HIV and Infectious Diseases, Baltic Medical Educational Centre - Chronic Hepatitis C: Pharmacoeconomic Aspects - Maintenance, Financing and Results of HIV Prevention Programs for Maternity and 19.02.15 St Petersburg 22. Conference "The Wrap-Up of 2014. The Difficult 2015". Pharmaceutical Association St Petersburg and The North West The Analysis of A New List of Vital and Most Important Drugs 2015 27.02.15 St Petersburg 23. XXXVII Concluding Scientific and Practical Conference "Current Issues in Children's Infectious Diseases 2015" HC, Association fo Neurologists, Research Institute for Children's Infections, St Petersburg State Pediatric Medical Institute, Association of Infectiologists of St Petersburg and Leningrad Oblast Cost effectiveness of Teratment and Prevention of Infectious Diseases 10.03.15 St Petersburg 24. School "Prostate Cancer" Russian Society of Clinical Oncology Pharmacoeconomic Aspects of Abiraterone Therapy of Metastatic Prostate Cancer 10.04.15 St Petersburg 25. Round Table "Medical Care and Drug Provision for Elderly Patients" Health Committee of the State Duma of the Federal Assembly Pharmacoeconomic Aspects of Treating Elderly Patients 08.06.15 Moscow 26. IV All-Russian Interregional Congress "Baltic Medical Forum" Autonomic nonprofit organization "Consultive and Information Centre "Medical Science and Technologies"" Pharmacoeconomic Aspects of Prevention, Diagnosis and Therapy of Socially Significant Diseases 24.06.15 St Petersburg 27. Scientific and Practical Conference "Rational Pharmacotherapy in Contemporary Endocrinology" Health Committee of St Petersburg, Professional Association of Clinical Pharmacologists of St Petersburg Pharmacoeconomic Aspects of SGLT2 Inhibitor Therapy for Type 2 Diabetes 25.06.15 St Petersburg 28. Scientific and Practical Conference "Uncomplicated Urinary Tract Infections. Unifying Standards and Clinical Practice" Health Committee Therapy for Acute Cystitis. Analysis of Evidence and Costs of Treatment 25.06.15 St Petersburg 29. Round Table "Lists of Drugs. Will Innovative Drugs Be Available for Patients?" Media Center of "Rossiyskaya Gazeta" Pharmacoeconomic Aspects of Innovative Drug Use 25.08.15 Moscow 30. International Congress "HIV Infections. Diagnostic, Therapeutic, Preventive, and Prognostic Issues" (VII Vinogradov Readings) RAS, HC,



Regional Chapter Annual Report - 2015

Pavlov First Saint Petersburg State Medical University, Institute of Experimental Medicine of North-Western Section of RAS, St Petersburg Centre for Prevention and Control of HIV and Infectious Diseases, Baltic Medical Educational Centre Pharmacoeconomic Aspects of Effective HAART Schemes 14.10.15 St Petersburg 31. Scientific and Practical Conference "Organization of Oncologic Care for the Population of Tver Oblast, Innovations in Oncology" HC Cost Effectiveness Assessment of Oncologic Care 19.10.15 Tver 32. Expert Council "HPV Vaccination Program in St Petersburg. Results of Implementation and Perspectives" HC Pharmacoeconomic Aspects of HPV Vaccination in the RF 29.10.15 St Petersburg III. Oral Presentations at the ISPOR International and European Meeting: 1. ISPOR 18 annual European Congress. Modeling the Inclusion of Drugs into the Russian Government's Reimbursement Lists. An analysis of the 2014 data. 9/11/2015 Milan IV. Poster Presentations at the ISPOR International and European Meeting: 1. ISPOR. 18TH ANNUAL EUROPEAN CONGRESS ISPOR. RESEARCH ABSTRACTS. Value in health. 2015:18(7); A442 BUDGET IMPACT ANALYSIS OF THE TREATMENT OF CHRONIC MYELOID LEUKEMIA WITH TYROSINE KINASE INHIBITORS - NILOTINIB IN THE FIRST AND SECOND LINES OF THERAPY. Kolbin A, Frolov M, Kurylev A, Vilum I, Balykina Y, Proskurin M 2. ISPOR. 18TH ANNUAL EUROPEAN CONGRESS ISPOR. RESEARCH ABSTRACTS. Value in health. 2015:18(7); A515. INVESTIGATING LEVELS OF BACTERIAL RESISTANCE AND ANTIBIOTIC CONSUMPTION IN THE ST. PETERSBURG STATE MEDICAL UNIVERSITY. Kolbin A, Lawson R, Kurylev A, Arepieva M3, Balykina Y, Spiridonova A, Mukhina N, Sidorenko S 3. ISPOR. 18TH ANNUAL EUROPEAN CONGRESS ISPOR. RESEARCH ABSTRACTS. Value in health. 2015:18(7); A443 PHARMACOECONOMIC ANALYSIS OF THE USE OF EVEROLIMUS COMPARED TO AXITINIB IN SECOND LINE THERAPY OF PATIENTS WITH METASTATIC RENAL CELL CARCINOMA. Kolbin A, Frolov M, Kurylev A, Balykina Y, Proskurin M 4. ISPOR. 18TH ANNUAL EUROPEAN CONGRESS ISPOR 1Abstract presentation code: PND18 Budget impact of perampanel for the treatment of patients with partial-onset seizures (POS) in Russia. Tremblay G., Patel V., Tsong W., Forsythe A., Moiseev A., Belousov D.U. 5. ISPOR. 18TH ANNUAL EUROPEAN CONGRESS ISPOR Abstract presentation code: PCN163 Pharmacoeconomic analysis of afatinib as 1st line treatment of metastatic non-small cell lung cancer with DEL19 mutation of epidermal growth factor receptor (EGFR) gene. Belousov D.U., Gorbunova V.A., Orlov S.V., Afanasyeva E.V. 6. ISPOR. 18TH ANNUAL EUROPEAN CONGRESS ISPOR 18th Annual European Congress, November 7 - 11, 2015, Milan, Italy. Poster presentation. Abstract presentation. Budget impact



Regional Chapter Annual Report - 2015

analysis of pramipexole extended release monotherapy in early Parkinson's disease Belousov D.U., Afanasyeva E.V. 7. ISPOR. 18TH ANNUAL EUROPEAN CONGRESS ISPOR 18th Annual European Congress, November 7 - 11, 2015, Milan, Italy. Poster presentation. Abstract presentation. Cost-effectiveness analysis of pramipexole extended release monotherapy in early Parkinson's disease Belousov D.U., Afanasyeva E.V. 8. ISPOR. 18TH ANNUAL EUROPEAN CONGRESS ISPOR Abstract presentation. Cost-utility analysis of pramipexole extended release monotherapy in early Parkinson's disease. Belousov D.U., Afanasyeva E.V.

Describe your Chapter's accomplishments for 2015 with regard to Policy-related activities.

1. Modeling the inclusion of drugs in the Russian government's reimbursement lists. This research we presented to the Federal Ministry of Health. 2. We are conducting pharmacoepidemiology research for State insurance Fund about using antibiotics in state hospitals in SPb.

Describe your Chapter's accomplishments for 2015 with regard to Chapter meetings or conferences.

1. Meeting about HTA into Life Sciences Invest. Partnering Russia. Saint Petersburg, 10-11/11/2015. 2. Meeting about HTA into St. Petersburg International Innovation Forum 2015, 9/10/2015

Describe your Chapter's accomplishments for 2015 with regard to membership engagement.

Is your Chapter affiliated with any institutions, universities, government or associations (other than ISPOR)? If yes, please list and describe the nature of these affiliations(s).

No

Does your Chapter collect membership dues or fees from individuals for local Chapter membership? If yes, how much are the dues?

No

How many ISPOR International members (paying dues to ISPOR Headquarters) does your Chapter have? Provide an estimate if you do not have an exact count.

4

Does your Chapter have any agreements or sponsorship arrangements with any for-profit companies, governments, health authorities or associations? If yes, please describe.

No

Does your Chapter employ paid administrative or management staff (Association Management Company, contracted staff)?

No

Other than the page for your Chapter on the ISPOR website, does your Chapter maintain a website?

Yes



Regional Chapter Annual Report - 2015

<http://www.labclinpharm.ru>;
<http://www.healtheconomics.ru>

When did your Chapter last update the ISPOR Chapter Constitution?

In the last 3 years.

Has your Chapter (as a group, not as individual members) submitted formal comments or responses to any government or health authority in 2014 or 2015? If yes, what was the topic or issue?

Yes

Modeling the inclusion of drugs in the Russian government's reimbursement lists. This research we presented to the Federal Ministry of Health.

Does your Chapter (as a group, not as individual members) interact in some way with the HTA or other official guidelines in your country? If yes, please name guideline(s) and describe.

Yes

Centre of Expertise and quality control of medical products. Moscow.

Does your Chapter have any committees or special interest groups? Please indicate and briefly describe.

Yes

1. Mathematical model for predicting the development of bacterial resistance

70

Academia %

Government/HTA Agency %

Industry %

Consulting %

Clinicians %

20

Student %

10

Other %

What benefits does your Chapter offers to its members?

International communication with colleagues from other countries

What are the most significant achievements of your Chapter in 2015?

1. Modeling the inclusion of drugs in the Russian government's reimbursement lists. This research we presented to the Federal Ministry of Health. 2. We are conducting pharmacoepidemiology research for State insurance Fund about using antibiotics in state hospitals in SPb.

What are the greatest challenges facing your Chapter?

taking part in the international conference due to the problems with funding



Regional Chapter Annual Report - 2015

How does your Chapter fulfill ISPOR's mission to promote health economics and outcomes research excellence to improve decision making for health globally? Describe how it supports the development and promotion of the discipline of health economics and outcomes research in your region.

How can the ISPOR organization as a whole (Staff, Board, Consortia, Networks, etc.) better support your Chapter?

Please indicate who prepared this report, include title, phone, email.

We have own educational courses. 1. Main issues of health technology assessment (technology used in health care. The schedule was 6 days a week during 1 month, totally 144 hours. May, 2015. Saint Petersburg. Name of sections and disciplines: Stages of drug development; Health technology assessment (HTA): history, goals, and the basic principles; Models and approaches for HTA; Effectiveness and efficacy of health technologies. Comparative studies; Adverse events; Basics of clinical and economic analysis. Pharmacoeconomics; Analysis of the results. Working with literature. Medical statistics; Reporting and publishing of the results; Development, adoption and evaluation of management decisions; Using HTA to justify the selection of therapy - some legal issues.

providing of the international recommendations for Pharmacoeconomics and Outcomes Research

Professor Alexey Kolbin, MD, PhD, Doctor of Science
Head of the department of clinical pharmacology and evidence-based medicine First Pavlov State Medical University of St. Peterburg Professor of Department of Pharmacology, Faculty of Medicine St. Petersburg State University 197022, Russia, St. Petersburg, Lva Tolstogo 6-8 Tel: 89217590449 mail: alex.kolbin@mail.ru